The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Open accessAbstract
A large number of adenoviral agents are being developed for the treatment of cancer. However, the treatment-related death of a patient with ornithine transcarbamylase deficiency following adenovirus administration by hepatic artery has led to serious concerns regarding the safety of intravascular adenovirus. Both replication-incompetent (rAd.p53, e.g., SCH58500) and replication-selective (dl1520, aka Onyx-015; CG7870) oncolytic adenoviruses, by intravascular administration, are in clinical trials. We review Phases I and I/II results from these clinical trials. dl1520 and rAd.p53 were well-tolerated following hepatic artery infusion at doses of up to 2×1012 and 2.5×1013 particles, respectively. At a dose of 7.5×1013 particles, rAd.p53 was associated with dose-limiting cardiac output suppression; dl1520 dose escalation did not proceed higher than 2×1012. Intravenous (i.v.) infusions of dl1520 and CG7870 have been well tolerated by i.v. infusion at doses of 2×1013 and 6×1012, respectively, without identification of a maximally tolerated dose to date. Mild/moderate transaminitis was demonstrated in some patients on both the hepatic arterial and i.v. trials at doses ≥1012 particles. Interleukin (IL)-6 and IL-10 were induced in a dose-dependent manner in most patients, but significant interpatient and intrapatient (on repeat doses) variabilities were demonstrated. Evidence of p53 gene expression (Ad.p53) or viral replication (dl1520) was demonstrated in the majority of patients receiving ≥1012 particles. Over 100 cancer patients have been treated with intravascular adenovirus constructs to date with an acceptable toxicity profile; further clinical trial testing appears appropriate in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Self-citationKhuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Self-citationHeise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Self-citationAttenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Gene Therapy Death Prompts Review of Adenovirus Vector
Marshall, E. (1999) · Science · doi:10.1126/science.286.5448.2244 · Cited by 760
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 635
Rodríguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., & Henderson, D. (1997) · PubMed · Cited by 584
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583
Self-citationKirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Self-citationGene therapy: adenovirus vectors
Kozarsky, K. F., & Wilson, J. M. (1993) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(93)90126-a · Cited by 419
Roelvink, P. W., Lee, G. M., Einfeld, D. A., Kovesdi, I., & Wickham, T. J. (1999) · Science · doi:10.1126/science.286.5444.1568 · Cited by 406
Nemunaitis, J. J., Ganly, I., Khuri, F. R., Arseneau, J. C., Kuhn, J., McCarty, T. M., Landers, S., Maples, P. B., Romel, L., Randlev, B., et al. (2000) · PubMed · Cited by 404
Self-citationDeWeese, T. L., van der Poel, H. G., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U. M., DeJong, R., Detorie, N. A., Rodríguez, R., et al. (2001) · PubMed · Cited by 385
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Urea Cycle Disorders: Diagnosis, Pathophysiology, and Therapy
Brusilow, S. W., & Maestri, N. E. (1996) · Advances in Pediatrics · doi:10.1016/s0065-3101(24)00072-0 · Cited by 353
Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., & zur Hausen, H. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9470-9478.1998 · Cited by 353
Cancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Nemunaitis, J., Swisher, S. G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D. D., Kemp, B. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.609 · Cited by 322
p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection
Goodrum, F. D., & Ornelles, D. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9479-9490.1998 · Cited by 289
A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.
Suzuki, K., Fueyo-Margareto, J., Krasnykh, V. N., Reynolds, P. N., Curiel, D. T., & Alemany, R. (2001) · PubMed · Cited by 286
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Self-citationHallenbeck, P. L., Chang, Y.-N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., & Chiang, Y. L. (1999) · Human Gene Therapy · doi:10.1089/10430349950017725 · Cited by 283
p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication
Harada, J. N., & Berk, A. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5333-5344.1999 · Cited by 259
Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301512 · Cited by 243
Self-citationWills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M.-T., Huang, W.-M., Johnson, D. E., Anderson, S. C., Wen, S. F., et al. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.9-1079 · Cited by 233
Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein
Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., & Wold, W. S. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6147-6155.2000 · Cited by 206
ONYX-015: Clinical data are encouraging
Kirn, D., Hermiston, T., & McCormick, F. (1998) · Nature Medicine · doi:10.1038/3902 · Cited by 203
Self-citationYu, D., Sakamoto, G. T., & Henderson, D. (1999) · PubMed · Cited by 193
Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., & Michael Korn, W. (2000) · Nature Medicine · doi:10.1038/80466 · Cited by 189
In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.
Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., & Kirn, D. H. (2000) · PubMed · Cited by 178
Self-citationAntitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu, D., Chen, Y., Dilley, J., Li, Y., Embry, M. G., Zhang, H., Nguyen, N. N. M., Amin, P., Oh, J., & Henderson, D. (2001) · PubMed · Cited by 173
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer
Hermiston, T. W. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9973 · Cited by 134
Reovirus as a novel oncolytic agent
Norman, K. L., & Lee, P. W. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9871 · Cited by 124
Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo, K., Maneval, D. C., Anderson, S. C., & Gutterman, J. U. (1996) · PubMed · Cited by 118
Gene Therapy Death — "Everyone Has to Share in the Guilt"
Jenks, S. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.2.98 · Cited by 58
Cited by
Targeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
Viral and nonviral delivery systems for gene delivery
Nayerossadat, N., Maedeh, T., & Ali, P. (2012) · Advanced Biomedical Research · doi:10.4103/2277-9175.98152 · Cited by 858
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Metadata
- Authors
- Reid, T., Warren, R., & Kirn, D.
- Venue
- Cancer Gene Therapy
- Published
- 2002-11-22
- Volume
- 9
- Issue
- 12
- Pages
- 979-986
- ISSN
- 0929-1903 (ISSN-L)
- 1476-5500
- OpenAlex
- W1972359936
- Cited by
- 258
- References
- 37
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.